Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech posted Q1 FY26 revenue of ₹3,126.77 lakhs, up about 22% from ₹2,565.85 lakhs in Q1 FY25. Total income rose to ₹3,191.31 lakhs. Net profit jumped to ₹78.14 lakhs from ₹46.82 lakhs, a 67% YoY increase, helped by better operating leverage. Total expenses grew 23% to ₹3,088.59 lakhs, with cost of materials and other expenses being the main drivers. The board also approved the re-appointment of Mr. Gursimran Singh as Whole Time Director for five years, subject to shareholder approval. The auditor (Narinder Kumar and Company) issued a clean limited review report with no qualifications.
Strong top-line and bottom-line growth in Q1, though margins remain thin (single-digit EBITDA margin). EPS appears lower year-on-year due to rounding on a small share base, but absolute profitability improved. Likely positive for the stock in the short term given the growth print.